Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Investors Lend Satori $15 Million, Hoping It Converts To An Alzheimer's Treatment

This article was originally published in The Pink Sheet Daily

Executive Summary

The venture-backed Cambridge, Mass. firm says it can get its small-molecule gamma-secretase modulator into the clinic next year.

You may also be interested in...



Beyond A-Beta: New Approaches To Alzheimer’s

The Alzheimer’s Association International Conference is under way in Vancouver through July 19, but some of the most anticipated news regarding drug development for the disease is likely to take place later this year. There’s plenty of hope, but not much optimism that pivotal trials for bapneuzumab and solanezumab will succeed. Regardless of the outcome, the results will have an impact on which approaches to Alzheimer’s come next—and how they get funded.

Beyond A-Beta: New Approaches To Alzheimer’s

The track record for anti-amyloid beta Alzheimer’s treatments has been dismal. If upcoming results from pivotal trials for bapineuzumab and solanezumab are disappointing, they won’t scuttle the approach completely, but much more attention would shift toward other targets. We highlight two targets that have gained more attention of late, extracellular tau and ApoE4, and a diverse group of scientists working to move their work forward.

Lilly To Cease Development Of Alzheimer's Drug

Eli Lilly announced August 17 it would halt development of its Phase III Alzheimer's drug candidate semagacestat, casting some doubt on the efficacy of novel gamma secretase inhibitor drugs and slowing Lilly's late-stage pipeline as the company struggles to replace future revenues that will be lost to drugs going off patent.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS073787

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel